Citation Impact
Citing Papers
Degradation of Fibrillar Collagen in a Human Melanoma Xenograft Improves the Efficacy of an Oncolytic Herpes Simplex Virus Vector
2006 StandoutNobel
Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
2005 Standout
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
2012 Standout
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
2008 Standout
TOR Signaling in Growth and Metabolism
2006 Standout
Hallmarks of Cancer: The Next Generation
2011 Standout
FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis
2010 StandoutNobel
Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type
2002
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
2009
Trial of oral miltefosine for visceral leishmaniasis
1998
The history of cancer epigenetics
2004 Standout
DNA methylation patterns and epigenetic memory
2002 Standout
Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy
1996
Epigenetics in human disease and prospects for epigenetic therapy
2004 StandoutNature
Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown
2018 StandoutNobel
Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents
1997
A Randomized Trial of Surgery in the Treatment of Single Metastases to the Brain
1990 Standout
Head and neck cancer
2008 Standout
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
Renal-Cell Carcinoma
1996 Standout
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies
2004
Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991-2001
2002
Ondansetron plus Metopimazine Compared with Ondansetron Alone in Patients Receiving Moderately Emetogenic Chemotherapy
1993
Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation
2000 Standout
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
Clinical applications of quinone-containing alkylating agents
2000
The efficacy of a combination of ondansetron, methyiprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy
1997
Antitumour actions of interferons: implications for cancer therapy
2016
Polyamines and cancer: implications for chemotherapy and chemoprevention
2013
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck
1998
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
2008 Standout
Thermal ablation of tumours: biological mechanisms and advances in therapy
2014 Standout
Midterm outcomes in patients with intermediate‐sized hepatocellular carcinoma
2010
Methodological issues in antiemetic studies
1993
Nasopharyngeal carcinoma
2015 Standout
Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment
2005
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis.
1994
Tuberous sclerosis
2008 Standout
Malignant Gliomas in Adults
2008 Standout
Gene Silencing in Cancer in Association with Promoter Hypermethylation
2003 Standout
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
2010 Standout
Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals
2003 Standout
DNA Methylation Inhibitors in the Treatment of Leukemias, Myelodysplastic Syndromes and Hemoglobinopathies: Clinical Results and Possible Mechanisms of Action
2000
Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network
2008 Standout
Epstein–Barr virus: 40 years on
2004 Standout
The Emerging Hallmarks of Cancer Metabolism
2016 Standout
Gut microbiota, metabolites and host immunity
2016 Standout
Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases
2007
mTOR-targeted therapy of cancer with rapamycin derivatives
2005
Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease
2003
Polyamines and cancer: old molecules, new understanding
2004
Interleukin‐6 and its receptor in cancer
2007
A phase II study of pemetrexed combined with cisplatin in patients with recurrent or metastatic nanopharyngeal carcinoma
2011
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis
1994
The fundamental role of epigenetic events in cancer
2002 Standout
Sirolimus for Kaposi's Sarcoma in Renal-Transplant Recipients
2005 Standout
Leishmaniasis
1999 Standout
Synthesis, Antitumor Activity, and Tolerability of Phospholipids Containing Nitrogen Homologues
1995
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Emerging DNA topoisomerase inhibitors as anticancer drugs
2004
Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer
2001
Chemotherapy of brain metastases: Current status
1984
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
Azacitidine Induces Demethylation of the Epstein-Barr Virus Genome in Tumors
2004
SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA
2000
Nonviral Vectors for Gene Delivery
2008 Standout
Impact of pretreatment thrombocytosis on survival in primary breast cancer
2003
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
1999
Spermidine in health and disease
2018 StandoutScience
Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation.
1994
IMMUNOTHERAPY FOR METASTATIC RENAL CELL CARCINOMA
1993
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
2008 Standout
Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer
2004
Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference
2007 StandoutNobel
Targeting Signal Transduction Pathways in Colorectal Cancer—More Than Skin Deep
2005
Clinical Efficacy, Tolerability, and Safety of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma
2004
Chemotherapy Options for Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
2006
Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma
2004
Inhibitors of the mammalian target of rapamycin
2005
Contribution of Dexamethasone to Control of Chemotherapy-Induced Nausea and Vomiting: A Meta-Analysis of Randomized Evidence
2000
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Vascular toxicity associated with antineoplastic agents.
1986
Advances in Copper Complexes as Anticancer Agents
2013 Standout
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
1999 Standout
Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications
2001
Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
2005
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
DNA Topoisomerases: Structure, Function, and Mechanism
2001 Standout
Dose translation from animal to human studies revisited
2007 Standout
Works of U. Bruntsch being referenced
A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck
1994
Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity
1997
Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC early clinical trials group
1994
Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: results of a phase II study
1998
Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer
1994
Prevention of Chemotherapy-Induced Nausea and Emesis in Patients Responding Poorly to Previous Antiemetic Therapy
1992
The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas
1987
Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nausea
1997
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors
2003
Moderate Dose Escalation for Advanced Stage Hodgkin’s Disease Using the Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Scheme and Adjuvant Radiotherapy: A Study of the German Hodgkin’s Lymphoma Study Group
1998
Lack of response in nine patients with breast cancer treated with fibroblast interferon
1984
Microangiopathic hemolytic anemia, a frequent complication of mitomycin therapy in cancer patients
1984
Phase II trial of diaziquone (AZQ) in advanced malignant melanoma
1983
Epirubicin in colorectal cancer
1985
Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?
1991
Phase I Study of Weekly Oral Miltefosine (Hexadecyl-Phosphocholine) in Cancer Patients
1991
Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group.
2000
Phase II study of recombinant human interferon-gamma in metastatic renal cell carcinoma.
1990